Content area

Abstract

Cytosine base editors (CBEs) efficiently generate precise C·G-to-T·A base conversions, but the activation-induced cytidine deaminase/apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like (AID/APOBEC) protein family deaminase component induces considerable off-target effects and indels. To explore unnatural cytosine deaminases, we repurpose the adenine deaminase TadA-8e for cytosine conversion. The introduction of an N46L variant in TadA-8e eliminates its adenine deaminase activity and results in a TadA-8e-derived C-to-G base editor (Td-CGBE) capable of highly efficient and precise C·G-to-G·C editing. Through fusion with uracil glycosylase inhibitors and further introduction of additional variants, a series of Td-CBEs was obtained either with a high activity similar to that of BE4max or with higher precision compared to other reported accurate CBEs. Td-CGBE/Td-CBEs show very low indel effects and a background level of Cas9-dependent or Cas9-independent DNA/RNA off-target editing. Moreover, Td-CGBE/Td-CBEs are more efficient in generating accurate edits in homopolymeric cytosine sites in cells or mouse embryos, suggesting their accuracy and safety for gene therapy and other applications.

Improved cytosine base editors are created by repurposing an adenine deaminase.

Details

Title
Re-engineering the adenine deaminase TadA-8e for efficient and specific CRISPR-based cytosine base editing
Author
Chen, Liang 1   VIAFID ORCID Logo  ; Zhu, Biyun 1 ; Ru, Gaomeng 1 ; Meng, Haowei 2   VIAFID ORCID Logo  ; Yan, Yongchang 2 ; Hong, Mengjia 1 ; Zhang, Dan 1 ; Luan, Changming 1 ; Zhang, Shun 1 ; Wu, Hao 2 ; Gao, Hongyi 1 ; Bai, Sijia 1 ; Li, Changqing 1 ; Ding, Ruoyi 1 ; Xue, Niannian 1 ; Lei, Zhixin 2 ; Chen, Yuting 3 ; Guan, Yuting 1   VIAFID ORCID Logo  ; Siwko, Stefan 4 ; Cheng, Yiyun 1 ; Song, Gaojie 1   VIAFID ORCID Logo  ; Wang, Liren 1 ; Yi, Chengqi 2   VIAFID ORCID Logo  ; Liu, Mingyao 5   VIAFID ORCID Logo  ; Li, Dali 1   VIAFID ORCID Logo 

 East China Normal University, Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, Shanghai, China (GRID:grid.22069.3f) (ISNI:0000 0004 0369 6365) 
 Peking University, School of Life Sciences, Beijing, China (GRID:grid.11135.37) (ISNI:0000 0001 2256 9319) 
 CAS Key Laboratory of Quantitative Engineering Biology, Center for Genome Engineering and Therapy, Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China (GRID:grid.458489.c) (ISNI:0000 0001 0483 7922) 
 Texas A&M University, Institute of Biosciences and Technology, Houston, USA (GRID:grid.264756.4) (ISNI:0000 0004 4687 2082) 
 East China Normal University, Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, Shanghai, China (GRID:grid.22069.3f) (ISNI:0000 0004 0369 6365); BRL Medicine, Inc., Shanghai, China (GRID:grid.22069.3f) 
Pages
663-672
Publication year
2023
Publication date
May 2023
Publisher
Nature Publishing Group
ISSN
10870156
e-ISSN
15461696
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2814206761
Copyright
© The Author(s), under exclusive licence to Springer Nature America, Inc. 2022. corrected publication 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.